A5090388430- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Blood groups and transfusion
- Platelet Disorders and Treatments
- Neutropenia and Cancer Infections
- Kruppel-like factors research
- Hemoglobinopathies and Related Disorders
- Eosinophilic Disorders and Syndromes
- Multiple Myeloma Research and Treatments
- Clinical Nutrition and Gastroenterology
- Histone Deacetylase Inhibitors Research
- Childhood Cancer Survivors' Quality of Life
- Renal Diseases and Glomerulopathies
- Complement system in diseases
- Immunodeficiency and Autoimmune Disorders
- Renal Transplantation Outcomes and Treatments
- Erythrocyte Function and Pathophysiology
- Pancreatic and Hepatic Oncology Research
- Sepsis Diagnosis and Treatment
- T-cell and Retrovirus Studies
Fred Hutch Cancer Center
2022-2025
Centre Hospitalier Universitaire d'Angers
2016-2025
Fédération Hospitalo-Universitaire, Paris Center for Microbiome Medicine
2018-2025
Nantes Université
2018-2025
Université d'Angers
2015-2025
Inserm
2016-2025
Centre National de la Recherche Scientifique
2016-2025
Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers
2016-2025
Centre Léon Bérard
2024
University of Washington
2022-2023
Abstract Among myeloproliferative neoplasms, polycythemia vera (PV) and essential thrombocythemia (ET) are the 2 entities associated with most chronic disease course. Leukemic evolution occurs rarely but has a grim prognosis. The interval between diagnosis leukemic is highly variable, from few years to >20 years. We performed molecular evaluation of 49 transformations PV ET by targeted next-generation sequencing. Using hierarchical classification, we identified 3 groups distinct time...
Failure of gastrointestinal acute graft-versus-host disease (GI-aGvHD) to respond steroid therapy is associated with limited further therapeutic options. We aimed assess the safety and efficacy first-in-human use pooled allogeneic faecal microbiota, MaaT013, for treatment steroid-refractory GI-aGvHD.This prospective, international, single-arm, phase 2a study reports clinical outcomes from a 24-patient cohort grade III-IV, refractory GI-aGvHD treated microbiota MaaT013. MaaT013 involved...
Central nervous system (CNS) thrombotic events are a well-known complication of acute lymphoblastic leukemia (ALL) induction therapy, especially with treatments including l-asparaginase (l-ASP). Data on risk factors and clinical evolution is still lacking in adult patients. We report the 22 CNS venous thrombosis cases occurring 708 adults treated for ALL or lymphoma (LL) Group Research Adult Acute Lymphoblastic Leukemia (GRAALL)-induction protocol, which included eight L-ASP (6,000 IU/m(2) )...
Venetoclax-azacitidine is the standard of treatment for unfit acute myeloid leukemia patients. In VIALE-A study, was given until progression but there are no data on its optimal duration responding patients who do not tolerate indefinite therapy. We retrospectively analyzed outcome discontinued venetoclax or venetoclax-azacitidine due to poor tolerance. Sixty-two newly diagnosed (ND) AML and 22 with morphological relapse refractory were included. ND cohort (n = 62), 28 stopped azacitidine 34...
The aim of our study was to analyze the potential survival benefit associated with HSCT according clinico-biological scores which incorporate molecular data (MIPSS70 and MIPSS70+V2) facilitate decision-making in this context. One transplant (n=241) one non-transplant cohorts (n=239) were used test hypothesis that PMF patients higher risk score from HSCT. A weighted propensity applied balance confounding factors transplanted cohort as reference. Weighted Cox proportional hazard models...
Because of the persistently high rates relapse patients with high-risk acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) following allogeneic hematopoietic stem cell transplantation (allo-HSCT), post-transplantation maintenance therapy has been proposed. We previously initiated a Phase II trial in which epigenetic was combined immunotherapy an attempt to reduce disease relapse. In that study, low-dose azacitidine (AZA) escalating doses donor lymphocyte infusion (DLI) were...
Although splenectomy is still considered the most effective curative treatment for immune thrombocytopenia (ITP), its use has significantly declined in last decade, especially since approval of thrombopoietin receptor agonists (TPO-RAs). The main objective study was to determine whether as nowadays, particularly patients with failure respond TPO-RAs. Our secondary assess, among who relapsed after splenectomy, pattern response treatments used before splenectomy. This multicenter retrospective...
The risk of immune thrombocytopenia (ITP) worsening during pregnancy and neonatal ITP (NITP) have never been prospectively studied. We included 180 pregnant 168 nonpregnant women with in a prospective, multicenter, observational cohort study. A total 131 were matched to by history splenectomy, status (no response, complete response), duration. Groups followed for 15 months. primary outcome was the first occurrence defined composite end point including bleeding events and/or severe (<30 ×...
Measurable residual disease (MRD) before hematopoietic cell transplantation (HCT) is an independent established prognostic factor in patients with acute myeloid leukemia (AML). Several methods exist to evaluate the presence of cells, but how these are used best combination unclear. In order examine cytogenetic abnormalities and MRD testing by multiparameter flow cytometry (MFC) may refine risk assessment HCT, we analyzed 506 adults cytogenetically abnormal AML who underwent both routine...
Multiparameter flow cytometry (MFC) measurable residual disease (MRD) before allogeneic hematopoietic cell transplantation (HCT) independently predicts poor outcomes in acute myeloid leukemia (AML). Conversely, its prognostic value the newly defined entity, myelodysplastic neoplasm (MDS)/AML is unknown. To assess relationship between type, pre-HCT MRD, and post-HCT outcomes, we retrospectively analyzed 1265 adults with MDS/AML (n = 151) or AML 1114) who received a first allograft second...
Patients with essential thrombocythemia (ET) have a chronic evolution risk of hematological transformation associated dismal outcome. Since patients resistance or intolerance an adverse prognosis, it is important to identify which patient will respond first-line treatment. We therefore aim describe the association between additional mutations and response treatment in ET. In this retrospective study, we analyzed molecular landscape 121 ET treated hydroxyurea (n=86) pegylated interferon...